Abstract
Malignant mesothelioma (MM) is a rare, highly aggressive tumor that arises from the surface serosal cells (pleural, peritoneal and pericardial cavities). Epidemiological and clinical data show that there is an association between asbestos exposure and MM development, even if the exact mechanism whereby asbestos induces MM is unknown. The continuing identification and elucidation of the molecular defects involved in mesothelioma pathogenesis and progression should lead to better disease control and greater therapeutic options in the near future. Goal of this article is to summarize the most recent advances in molecular pathogenesis of mesothelioma with particular emphasis on genes that could be considered as biomarkers or therapeutic targets and discuss possible clinical implications of these findings.
Keywords: Mesothelioma, pathogenesis, biomarkers, cDNA array
Current Cancer Drug Targets
Title: Biological Agents Involved in Malignant Mesothelioma: Relevance as Biomarkers or Therapeutic Targets
Volume: 10 Issue: 1
Author(s): S. Crispi, I. Cardillo, E. P. Spugnini, G. Citro, S. Menegozzo and A. Baldi
Affiliation:
Keywords: Mesothelioma, pathogenesis, biomarkers, cDNA array
Abstract: Malignant mesothelioma (MM) is a rare, highly aggressive tumor that arises from the surface serosal cells (pleural, peritoneal and pericardial cavities). Epidemiological and clinical data show that there is an association between asbestos exposure and MM development, even if the exact mechanism whereby asbestos induces MM is unknown. The continuing identification and elucidation of the molecular defects involved in mesothelioma pathogenesis and progression should lead to better disease control and greater therapeutic options in the near future. Goal of this article is to summarize the most recent advances in molecular pathogenesis of mesothelioma with particular emphasis on genes that could be considered as biomarkers or therapeutic targets and discuss possible clinical implications of these findings.
Export Options
About this article
Cite this article as:
Crispi S., Cardillo I., Spugnini P. E., Citro G., Menegozzo S. and Baldi A., Biological Agents Involved in Malignant Mesothelioma: Relevance as Biomarkers or Therapeutic Targets, Current Cancer Drug Targets 2010; 10 (1) . https://dx.doi.org/10.2174/156800910790980232
DOI https://dx.doi.org/10.2174/156800910790980232 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aurora B: A New Prognostic Marker and Therapeutic Target in Cancer
Current Medicinal Chemistry A Wnt-ow of Opportunity: Targeting the Wnt/β-Catenin Pathway in Breast Cancer
Current Drug Targets Role of miRNAs in Cancer Diagnostics and Therapy: A Recent Update
Current Pharmaceutical Design Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy
Current Gene Therapy Toxicity of Carbon Nanotubes
Current Drug Metabolism Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets Therapeutic Value of Black Seed Oil in Methotrexate Hepatotoxicity in Egyptian Children with Acute Lymphoblastic Leukemia
Infectious Disorders - Drug Targets Estrogen Receptor Beta (ERβ) Expression in Different Subtypes of Malignant Pleural Mesothelioma
Current Respiratory Medicine Reviews Redox-inactive Analogue of Tocotrienol as a Potential Anti-cancer Agent
Anti-Cancer Agents in Medicinal Chemistry Effects of Specific Cyclooxygenase-2 Inhibitors on Carcinogenesis
Medicinal Chemistry Reviews - Online (Discontinued) Recent Advances in Small Molecule Prodrugs for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design The Role of PET/CT and SPECT/CT in Oncology Drug Development
Current Molecular Imaging (Discontinued) Targeted Therapies in Gynecologic Cancers
Current Cancer Drug Targets Identification of Marker Genes for Cancer Based on Microarrays Using a Computational Biology Approach
Current Bioinformatics MicroRNA-dependent Regulation of Telomere Maintenance Mechanisms: A Field as Much Unexplored as Potentially Promising
Current Pharmaceutical Design Nanomaterial Based Approaches for the Diagnosis and Therapy of Cardiovascular Diseases
Current Pharmaceutical Design A Better Platinum-Based Anticancer Drug Yet to Come?
Anti-Cancer Agents in Medicinal Chemistry The Role of CD40 Expression in Dendritic Cells in Cancer Biology; A Systematic Review
Current Cancer Drug Targets New Platinum and Ruthenium Complexes - the Latest Class of Potential Chemotherapeutic Drugs - a Review of Recent Developments in the Field
Mini-Reviews in Medicinal Chemistry